ImmuCell amends supply agreement: Re-Tain deal terminates Nov 30, 2024 if FDA not approved

IMMUCELL CORP /DE/

Agreement auto-terminates on Nov 30, 2024 unless FDA approval for Re-Tain is received by then.
New payment terms: 75% invoiced monthly during production; 25% final balance on dispatch after FDA OK.
If no FDA approval by Nov 30, 2024, final balance is invoiced and agreement expires.
Updated Schedule 7 projects ~160,000 commercial units with expiration 4Q25-1Q26.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

IMMUCELL CORP /DE/ amended Amending Agreement with Norbrook Laboratories Limited (effective 2024-03-04).

Action: amendment
Agreement: supply
Counterparty: Norbrook Laboratories Limited
Effective: 2024-03-04

Exact text from the filing

On March 4, 2024, ImmuCell Corporation (the “Company”) entered into an Amending Agreement (the “Amendment”) with Norbrook Laboratories Limited (“Norbrook”), which Amendment amends that certain Development Services and Commercial Supply Agreement, dated September 5, 2019, by and between the Company and Norbrook (as amended to date, the “Agreement”).

View on SEC.gov

739 material agreements filed in the last 30 days. Browse all material agreements →

IMMUCELL CORP /DE/ filing history →

Source: SEC EDGAR

accession 0001213900-24-020389

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.